STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2515 by analyst upside · 2026-06-27
TMO
Thermo Fisher Scientific Inc.
Healthcare · Market Cap $191B · P/E 28.2x
ANALYST PRICE TARGET
+16.8%
implied upside to consensus target
Current Price $513.03
Consensus Target $599.19
Bull Target $750.0
Bear Target $490.0
Analysts Covering 26
ANALYST CONSENSUS — BUY
Strong Buy
6
Buy
18
Hold
3
Sell
0
52-Week Low $401.45
52-Week High $643.99
YTD Return -13.2%
FUNDAMENTALS
Market Cap $191B
P/E Ratio (TTM) 28.2x
Forward P/E 18.8x
EPS (TTM) $18.21
PEG Ratio 1.62
Dividend Yield 0.37%
Revenue (TTM) $45.2B
Profit Margin 15.2%
52-WEEK RANGE
52-Week Low $401.45
52-Week High $643.99
Current Price $513.03
Bear Target $490.0
Bull Target $750.0
● Now $513.03 ● Target $599.19
TRADING DATA
Avg Volume 2.3M
YTD Return -13.2%
Analyst Count 26
Consensus Buy
Upside to Target +16.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Thermo Fisher Scientific Inc. (TMO) is currently trading at $513.03 with a Wall Street consensus price target of $599.19, implying potential upside of 16.8% over the next 12 months. 26 analysts currently cover TMO, with a consensus rating of Buy — 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $750.0, while the most cautious has a target of $490.0.

TMO operates in the Healthcare sector with a market capitalisation of $191B. The stock is down 13.2% year-to-date and is currently trading near the lower end of its 52-week range of $401.45 – $643.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TMO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler ● Initiated
Neutral 2026-06-11 14% win rate (7 calls)
HSBC ↓ Downgrade
Buy → Hold 2026-06-03 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-08 Building track record
Stifel — Reiterated
Buy → Buy 2026-04-24 Building track record
Baird — Reiterated
Outperform → Outperform 2026-04-24 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-04-14 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-04-06 Building track record
Citigroup — Reiterated
Buy → Buy 2026-01-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →